AI Article Synopsis
- * In a study using a mouse model of VaD, low-dose levamlodipine besylate (0.1 mg/kg) improved cognitive functions, as evidenced by better performance in the Morris Water Maze (MWM) test.
- * Levamlodipine besylate treatment also partially restored certain brain signaling proteins in the hippocampus, indicating its potential as a therapeutic option for enhancing cognitive functions in individuals with VaD.
Article Abstract
Vascular dementia (VaD) is a complex disorder caused by reduced blood flow in the brain. However, there is no effective pharmacological treatment option available until now. Here, we reported that low-dose levamlodipine besylate could reverse the cognitive impairment in VaD mice model of right unilateral common carotid arteries occlusion (rUCCAO). Oral administration of levamlodipine besylate (0.1 mg/kg) could reduce the latency to find the hidden platform in the MWM test as compared to the vehicle group. Furthermore, vehicle-treated mice revealed reduced phospho-CaMKII (Thr286) levels in the hippocampus, which can be partially restored by levamlodipine besylate (0.1 mg/kg and 0.5 mg/kg) treatment. No significant outcome on microglia and astrocytes were observed following levamlodipine besylate treatment. This data reveal novel findings of the therapeutic potential of low-dose levamlodipine besylate that could considerably enhance the cognitive function in VaD mice.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890753 | PMC |
| http://dx.doi.org/10.1038/s41598-019-47868-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical assessment of levamlodipine besylate combination therapy for essential hypertension: A protocol for systematic review and meta-analysis.
Medicine (Baltimore)
April 2022
Department of Pharmacy, General Hospital of Eastern Theater Command, Nanjing, Jiangsu Province, China.
Background: Essential hypertension has been regarded a significant risk factor for cardiovascular disease across the globe, and a significant escapable causation of early death as well as morbidity in the U.S. When angiotensin II receptor blockers and calcium channel blockers are used to treat essential hypertension, most patients will have inadequate blood pressure management.
View Article and Find Full Text PDFBackground: Hypertension and hyperhomocysteinemia (HHcy) have long been associated with adverse cardiovascular and cerebrovascular health outcomes. This study evaluated the effect of individualized administration of folic acid (FA) on homocysteine (Hcy) levels, prothrombotic state, and blood pressure (BP) in patients with H-type hypertension (combination of HHcy and hypertension).
Methods: In this double-blinded, randomized clinical cohort study, 126 patients with H-type hypertension who were treated at our hospital were randomly divided into treatment and control groups (n = 55 each).
Basilar dolichoectasia with intermural hematoma accompanied by cerebral microbleeds and white matter hyperintensities: A case report.
Medicine (Baltimore)
August 2021
Department of Neurology, The First Hospital of Shanxi Medical University, Taiyuan, China.
Rationale: The clinical manifestations of basilar dolichoectasia (BD) are variable. The diagnosis is based on imaging measurements. Digital subtraction angiography displays only the dilated vascular lumen and lacks visualization of the arterial wall.
View Article and Find Full Text PDFBioequivalence of levamlodipine besylate tablets in healthy Chinese subjects: a single-dose and two-period crossover randomized study.
BMC Pharmacol Toxicol
November 2020
Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Background: Levamlodipine, a calcium channel blocker, has been show act as a cardiovascular drug. To compare the pharmacokinetic parameters between levamlodipine (test formulation) at a single dose of 5 mg and amlodipine (reference formulation) at a single dose of 10 mg, the bioequivalence study was carried out.
Methods: A single-dose randomized, open-label, two-period crossover study was designed in healthy Chinese subjects.
Effect of low-dose Levamlodipine Besylate in the treatment of vascular dementia.
Sci Rep
December 2019
College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou, China.
Article Synopsis
- * In a study using a mouse model of VaD, low-dose levamlodipine besylate (0.1 mg/kg) improved cognitive functions, as evidenced by better performance in the Morris Water Maze (MWM) test.
- * Levamlodipine besylate treatment also partially restored certain brain signaling proteins in the hippocampus, indicating its potential as a therapeutic option for enhancing cognitive functions in individuals with VaD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!